Sutro Biopharma Inc. is a leading clinical-stage company that specializes in the development and production of next-generation cancer therapeutics. With their proprietary cell-free protein synthesis platform, they are able to rapidly and efficiently design and create novel antibody-drug conjugates and bispecific antibodies. Their innovative approach has the potential to revolutionize cancer treatment and improve patient outcomes.